Our products are built on the Click Neurobehavioral Intervention (CNI) platform and powered by Clickometrics®, our machine learning and data science engine.

Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Polyfins Technology uses Artificial Intelligence to help improve the quality of life for people with chronic skin conditions such as Eczema and Psoriasis. The company has developed a digital therapeutic solution, EczemaLess. Its solution uses AI to detect the severity of Eczema, improve adherence to care plans and find the co-relation between triggers, treatments, and flareups.

Polyfins Technology uses Artificial Intelligence to help improve the quality of life for people with chronic skin conditions such as Eczema and Psoriasis. The company has developed a digital therapeutic solution, EczemaLess. Its solution uses AI to detect the severity of Eczema, improve adherence to care plans and find the co-relation between triggers, treatments, and flareups.